Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients

Busaya Kulabusaya1,2, Somratai Vadcharavivad3, Yingyos Avihingsanon4

  • 1Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.

Insights

Mycophenolic acid exposure in Asian kidney transplant recipients on day 3 post-transplantation with mycophenolate mofetil (1.5 g/d) was comparable to the target AUC. Reduced renal function significantly impacts mycophenolic acid exposure.

Area of Science:

  • Pharmacokinetics and clinical outcomes in transplantation medicine.
  • Immunosuppressive drug monitoring in organ recipients.

Background:

  • Early post-transplant mycophenolic acid (MPA) exposure effects are known, but not specifically in Asian kidney transplant recipients using 1.5 g/d mycophenolate mofetil (MMF).
  • Investigating MPA exposure is crucial for optimizing immunosuppression and preventing rejection in this population.

Purpose of the Study:

  • To determine MPA exposure (AUC) on day 3 post-transplantation in Asian kidney transplant recipients receiving 1.5 g/d MMF.
  • To evaluate the impact of reduced renal function on MPA AUC and its relation to biopsy-proven acute rejection (BPAR).

Main Methods:

  • Blood and 24-h urine samples collected on day 3 post-kidney transplantation.
  • MPA area under the concentration-time curve (AUC) calculated using the linear trapezoidal rule.
  • MPA AUC compared to a target of 45 mg*h/L; effects of renal function (urine output, CrCl) and BPAR incidence assessed.

Main Results:

  • Mean MPA AUC (45.1 mg*h/L) was comparable to the target of 45 mg*h/L in 42 Thai kidney transplant recipients (P=0.962).
  • Significantly lower MPA AUC observed in patients with urine output <2400 mL (35.3) vs. ≥2400 mL (47.4) (P=0.002).
  • MPA AUC was lower in patients with CrCl <25 mL/min (38.0) vs. ≥25 mL/min (49.2) (P=0.017).
  • BPAR incidence was similar between patients with MPA AUC <45 and ≥45 mg*h/L (20.0% vs. 23.5%, P=1.000).

Conclusions:

  • A starting dose of 1.5 g/d MMF achieves a comparable mean MPA AUC on day 3 post-kidney transplantation.
  • Severely reduced renal function significantly influences MPA exposure in kidney transplant recipients.
  • MPA AUC on day 3 did not correlate with acute rejection rates in this cohort.

Related Concept Videos

Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
159
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
375
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
370
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
240
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
349
Dosage Compensation02:50

Dosage Compensation

In animals, gender is determined by the number and type of sex chromosome. For example, human females have two X chromosomes, and males have one X and one Y chromosome, whereas C.elegans with one X chromosome is a male, and the one with two X chromosomes is a hermaphrodite.
In addition to sexual development, the X chromosome has genes involved in autosomal functions such as brain development and the immune system. Therefore, males and females with  distinct numbers of X chromosomes will...
7.1K